Utidelone has the ability to cross BBB due to its unique physicochemical characteristic and insusceptibility to P-glycoprotein-mediated efflux
The company has now received 100% of the incentive owed to the company for the financial year 2022-23 under the PLI scheme
Executes the first project for developing and manufacturing a novel anticancer mAb
Liraglutide is a drug-device combination formulation used in the treatment of Type 2 Diabetes Mellitus
Under this agreement, lpca will grant to Omexa a non-exclusive right to research, develop, manufacture and market an anti-cancer biosimilar for the global market
Under the arrangement, Dr. Reddy's will have exclusive rights to promote and distribute Sanofi's vaccine brands Hexaxim, Pentaxim, Tetraxim, Menactra, FluQuadri, Adacel and Avaxim 80U
Pharma Solutions operates 10 research and development and/or production sites globally
Lonza plans to invest approximately CHF 500 million to upgrade the facility
Subscribe To Our Newsletter & Stay Updated